-
公开(公告)号：US07888498B2
公开(公告)日：2011-02-15
申请号：US11751283
申请日：2007-05-21
申请人： Antonin De Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
发明人： Antonin De Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
CPC分类号： C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y207/1101 , C12N2310/3521
摘要： The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases, caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
摘要翻译： 本发明涉及用于抑制IKK-B基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸，长度通常为19-25个核苷酸的核苷酸序列的反义链，以及 其基本上与IKK-B基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于使用该药物组合物治疗由IKK-B基因的表达或活化引起的疾病的方法; 以及抑制细胞中IKK-B基因表达的方法。
-
公开(公告)号：US08344127B2
公开(公告)日：2013-01-01
申请号：US13090580
申请日：2011-04-20
申请人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Sprague
发明人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Sprague
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
摘要翻译： 本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂 的RNAi试剂到β-ENaC。
-
公开(公告)号：US08344131B2
公开(公告)日：2013-01-01
申请号：US13355930
申请日：2012-01-23
申请人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
发明人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
公开(公告)号：US20110045473A1
公开(公告)日：2011-02-24
申请号：US12811511
申请日：2008-12-31
CPC分类号： G01N33/86 , C12N15/111 , C12N15/1137 , C12N2310/14 , C12Y304/21021 , G01N2333/96447 , Y10T436/143333
摘要： The invention features a method of identifying therapeutically relevant compositions that include a therapeutic agent and a delivery component by screening for an effect of the agent on the liver of a model subject.
摘要翻译： 本发明的特征在于通过筛选试剂对模型受试者的肝脏的影响来鉴定包括治疗剂和递送组分的治疗相关组合物的方法。
-
公开(公告)号：US20110224282A1
公开(公告)日：2011-09-15
申请号：US13043228
申请日：2011-03-08
申请人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
发明人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
IPC分类号： A61K31/713 , C07H21/02 , A61P27/02 , C12N5/071 , C12N5/09
CPC分类号： C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
摘要翻译： 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
公开(公告)号：US20070134236A1
公开(公告)日：2007-06-14
申请号：US10536067
申请日：2003-11-25
申请人： Antonin De Fougerolles , Victor Kotelianski , Ellen Garber , Carl Reid , Jose Saldanha , Herman Vlijmen
发明人： Antonin De Fougerolles , Victor Kotelianski , Ellen Garber , Carl Reid , Jose Saldanha , Herman Vlijmen
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06 , C07K16/18
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
摘要翻译： 本发明提供结合多种b趋化因子，特别是单核细胞趋化蛋白MCP-1，MCP-2和MCP-3的人源化抗体。 本发明还提供治疗药物和治疗与有害MCP活性相关的疾病的方法。
-
公开(公告)号：US20110034537A1
公开(公告)日：2011-02-10
申请号：US12867230
申请日：2009-02-12
申请人： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
发明人： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
IPC分类号： A61K31/713 , C07H21/02 , C12N5/10 , C12N5/071 , C12N15/63 , A61P37/02 , A61P31/12 , A61P31/16 , A61P31/14
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/17 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
摘要翻译： 本发明涉及用于抑制CD45基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US08912316B2
公开(公告)日：2014-12-16
申请号：US13612521
申请日：2012-09-12
申请人： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
发明人： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
IPC分类号： C12Q1/68 , C12N15/113
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/17 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
摘要翻译： 本发明涉及用于抑制CD45基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US08598335B2
公开(公告)日：2013-12-03
申请号：US13614836
申请日：2012-09-13
申请人： Antonin De Fougerolles , John Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
发明人： Antonin De Fougerolles , John Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
公开(公告)号：US08344129B2
公开(公告)日：2013-01-01
申请号：US13355879
申请日：2012-01-23
申请人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
发明人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.057 秒)
